Method for increasing the permeability of an epithelial barrier
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61N-001/30
A61M-037/00
출원번호
US-0641500
(2011-04-27)
등록번호
US-9586044
(2017-03-07)
국제출원번호
PCT/IB2011/051863
(2011-04-27)
§371/§102 date
20130222
(20130222)
국제공개번호
WO2012/046149
(2012-04-12)
발명자
/ 주소
Ross, Russell Frederick
출원인 / 주소
Kimberly-Clark Worldwide, Inc.
대리인 / 주소
Dority & Manning, P.A.
인용정보
피인용 횟수 :
1인용 특허 :
100
초록▼
Disclosed are nanotopography-based methods and devices for interacting with a component of epithelial tissue and increasing the permeability of the tissue. Devices include structures fabricated on a surface to form a nanotopography. A random or non-random pattern of structures may be fabricated such
Disclosed are nanotopography-based methods and devices for interacting with a component of epithelial tissue and increasing the permeability of the tissue. Devices include structures fabricated on a surface to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Microneedles may be beneficially utilized for delivery of an agent to a cell or tissue. Devices may be utilized to directly or indirectly alter cell behavior through the interaction of a fabricated nanotopography with the components of epithelial tissue.
대표청구항▼
1. A method for increasing the permeability of a cellular layer that comprises epithelial cells, the method comprising: contacting the cellular layer with a microneedle, the microneedle including a plurality of nanostructures and microstructures formed on an external surface thereof in a predetermin
1. A method for increasing the permeability of a cellular layer that comprises epithelial cells, the method comprising: contacting the cellular layer with a microneedle, the microneedle including a plurality of nanostructures and microstructures formed on an external surface thereof in a predetermined pattern, wherein at least a portion of the microstructures have a cross-sectional dimension of greater than about 500 nanometers and less than about 10 micrometers and a height of from about 20 nanometers to about 1 micrometer, the cross-sectional dimension of the microstructures being greater than the height of the microstructures, wherein at least a portion of the nanostructures having a cross-sectional dimension of from about 5 nanometers to about 500 nanometers, wherein subsequent to contact between the cellular layer and the microneedle, the cellular layer exhibits increased permeability to the drug compound. 2. The method according to claim 1, wherein subsequent to contact between the cellular layer and the microneedle, the transepithelial electrical resistance of the cellular layer is less than about 95% of the transepithelial electrical resistance of the layer prior to contact with the microneedle. 3. The method according to claim 1, wherein subsequent to the contact between the cellular layer and the microneedle, the transepithelial electrical resistance of the cellular layer is less than about 85%, of the transepithelial electrical resistance of the layer prior to contact with the microneedle. 4. The method according to claim 1, wherein subsequent to the contact between the cellular layer and the microneedle, the transepithelial electrical resistance of the cellular layer is less than about 70% of the transepithelial electrical resistance of the layer prior to contact with the microneedle. 5. The medical device of claim 1, further comprising second nanostructures having a cross-sectional dimension less than the cross-sectional dimension of the microstructures and greater than the cross-sectional dimension of the plurality of nanostructures. 6. The method according to claim 1, wherein the cellular layer is skin. 7. The method according to claim 1, the method changing the structure of an intercellular junction. 8. The method according to claim 7, wherein the intercellular junction is a tight junction. 9. The method according to claim 1, wherein the microneedle contains a channel that is in fluid communication with a drug compound. 10. The method according to claim 9, wherein the drug compound is a protein therapeutic. 11. The method according to claim 10, wherein the drug compound has a molecular weight greater than about 100 kDa. 12. The method according to claim 9, wherein the drug compound is delivered by the microneedle and permeates across the cellular layer via paracellular transport. 13. The method according to claim 9, wherein the drug compound is delivered by the microneedle and permeates across the cellular layer via transcellular transport. 14. The method according to claim 9, wherein drug compound is held within a reservoir. 15. The method according to claim 1, wherein at least a portion of the nanostructures have an aspect ratio of from about 0.2 to about 5. 16. The method according to claim 1, wherein the pattern has a fractal dimension of greater than about 1. 17. The method according to claim 1, wherein at least a portion of the nanostructures have a cross-sectional dimension of from about 100 to about 300 nanometers. 18. The method according to claim 1, wherein the nanostructures have approximately the same cross-sectional dimension. 19. The method according to claim 1, wherein at least a portion of the nanostructures have a center-to-center spacing of from about 50 nanometers to about 1 micrometer. 20. The method according to claim 1, wherein the ratio of the cross sectional dimension of two adjacent nanostructures to the center-to-center spacing between those two structures is between about 1:1 and about 1:4. 21. The method according to claim 1, wherein at least a portion of the nanostructures have an equidistant spacing. 22. The method according to claim 1, wherein at least a portion of the nanostructures have a height of from about 10 nanometers to about micrometer. 23. The method according to claim 1 wherein at least a portion of the nanostructures have an aspect ratio of from about 0.5 to about 3.5. 24. The method according to claim 9, wherein the drug compound is a TNF-α blocker. 25. The method according to claim 1, wherein the microneedle contains a channel for delivering the drug compound. 26. The method according to claim 1, wherein at least a portion of the nanostructures have a cross-sectional dimension of from about 20 to about 400 nanometers and at least a portion of the microstructures have a cross-sectional dimension of from about 600 nanometers to about 1.5 micrometers. 27. The method according to claim 1, wherein at least a portion of the nanostructures have a height greater than a cross-sectional dimension. 28. The method according to claim 1, wherein at least a portion of the nanostructures are in the form of pillars.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (100)
Frazier,A. Bruno; Andrade,Joseph D.; Bartholomeusz,Daniel A.; Brazzle,John D., Active needle devices with integrated functionality.
Urquhart John (Palo Alto CA) Chandrasekaran Santosh Kumar (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Bandage for transdermally administering scopolamine to prevent nausea.
Cho, Dong-il; Paik, Seung Joon; Lim, Jung Min; Lee, Ah Ra; Byun, Sang Won; Koo, Kyo-In, Barb-wired micro needle made of single crystalline silicon and biopsy method and medicine injecting method using the same.
Shah Kishore (Bridgewater NJ) Kydonieus Agis (Kendall Park NJ), Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate c.
Nealey, Paul F.; DePablo, Juan J.; Cerrina, Francesco; Solak, Harun H.; Yang, XiaoMin; Peters, Richard D.; Wang, Qiang, Guided self-assembly of block copolymer films on interferometrically nanopatterned substrates.
Johnson, Peter R.; Emery, Marla R.; Wolter, James T.; Raeder-Devens, Jennifer E.; Duan, Daniel C.; David, Moses M.; Choi, Hye-Ok, Masking method for coating a microneedle array.
Dubrow, Robert S.; Bock, Lawrence A.; Daniels, R. Hugh; Hardev, Veeral D.; Niu, Chunming; Sahi, Vijendra, Medical device applications of nanostructured surfaces.
Mukerjee, Erik V.; Smith, Rosemary L., Method and/or apparatus for puncturing a surface for extraction, in situ analysis, and/or substance delivery using microneedles.
Sherman, Faiz Feisal; Gartstein, Vladimir, Method for manufacturing microstructures having hollow microelements using fluidic jets during a molding operation.
Campbell Patricia S. (Palo Alto CA) Enscore David J. (Sunnyvale CA) Gale Robert M. (Los Altos CA) Kaufman Arnold (Palo Alto CA), Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix.
Van Rijn, Cornelis Johannes Maria; Vogelaar, Laura; Nijdam, Wietze; Barsema, Jonathan Nathaniel; Wessling, Matthias, Method of making a product with a micro or nano sized structure and product.
Delmore, Michael D.; Fleming, Patrick R.; Huntley, Douglas A.; Keister, Jamieson C.; Thomas, Cristina U.; Ferber, Richard H., Microneedle arrays and methods of manufacturing the same.
Laermer, Franz; Stumber, Michael; Scholten, Dick; Maeurer, Christian, Microneedles to be placed in the skin for the transdermal application of pharmaceuticals.
Borenstein, Jeffrey T.; Carter, David; Vacanti, Joseph P., Nanotopographic compositions and methods for cellular organization in tissue engineered structures.
Duerig, Urs T.; Frommer, Jane E.; Gotsmann, Bernd W.; Hedrick, James L.; Knoll, Armin W.; Miller, Robert D.; Pires, David; Wade, Charles G., Patterning nano-scale patterns on a film comprising unzipping polymer chains.
Lothar W. Kleiner ; Robert M. Gale ; Randall G. Berggren ; Gilbert T. Tong ; Guohua Chen ; Keith E. Dionne ; Paul R. Houston, Rate controlling membranes for controlled drug delivery devices.
Osborne James L. (Mountain View CA) Nelson Melinda (Sunnyvale CA) Enscore David J. (Saratoga CA) Yum Su I. (Los Altos CA) Gale Robert M. (Los Altos CA), Subsaturated nicotine transdermal therapeutic system.
Osborne James L. (Mountain View CA) Nelson Melinda (Sunnyvale CA) Enscore David J. (Saratoga CA) Yum Su I. (Los Altos CA) Gale Robert M. (Los Altos CA), Subsaturated nicotine transdermal therapeutic system.
Enscore David J. (Sunnyvale CA) Campbell Patricia S. (Palo Alto CA) Osborne James L. (Mountain View CA) Smart Melinda K. (Sunnyvale CA) Yum Su I. (Los Altos CA), Subsaturated transdermal therapeutic system having improved release characteristics.
Enscore David J. (Sunnyvale CA) Campbell Patricia S. (Palo Alto CA) Osborne James L. (Mountain View CA) Smart Melinda K. (Sunnyvale CA) Yum Su I. (Los Altos CA), Subsaturated transdermal therapeutic system having improved release characteristics.
Enscore David J. (Sunnyvale CA) Campbell Patricia S. (Palo Alto CA) Osborne James L. (Mountain View CA) Smart Melinda K. (Sunnyvale CA) Yum Su I. (Los Altos CA), Subsaturated transdermal therapeutic system having improved release characteristics.
Chandrasekaran Santosh K. (Palo Alto CA) Darda Siegfried (Ingelheim am Rhein CA DEX) Michaels Alan S. (Atherton CA) Cleary Gary W. (Palo Alto CA), Therapeutic system for administering clonidine transdermally.
Gale Robert M. (Los Altos CA) Goetz Victor (Palo Alto CA) Lee Eun S. (Redwood City CA) Taskovich Lina T. (Palo Alto CA) Yum Su I. (Los Altos CA), Transdermal administration of fentanyl and device therefor.
Nabel Elizabeth G. (Ann Arbor MI) Nabel Gary J. (Ann Arbor MI), Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.